Thank you Gilead Sciences, Inc. for your support on this FAQ Video Module.

In this engaging update from the Allied Digestive Health Annual Conference, Dr. Sonal Kumar, hepatologist at Weill Cornell Medicine, shares the latest advancements in diagnosing and managing Primary Biliary Cholangitis (PBC). Dr. Kumar emphasizes the importance of early assessment and intervention—highlighting the limitations of outdated treatment algorithms that delay evaluation for second-line therapy. Instead, clinicians are now encouraged to assess patients as early as 6 months after starting ursodeoxycholic acid (UDCA), especially those with elevated alkaline phosphatase (ALP), advanced fibrosis, or younger age. The discussion also explores the evolving treatment goals in PBC, including a shift toward normalization of ALP and bilirubin levels as key biomarkers of disease activity and prognosis. Dr. Kumar highlights exciting data from the ELATIVE and RESPONSE trials, which led to the approval of two new PPAR agonists—elafibranor and seladelpar—offering improved ALP normalization rates and even symptom relief for pruritus. This marks a significant turning point in how hepatologists approach symptom management in PBC, with fatigue and pruritus now recognized as critical components of care. Learn more about this evolving treatment landscape and how these advancements are shaping a more personalized, proactive approach for patients living with PBC.